Financial News Feed

Today AXDX ranks # as BUY CANDIDATE.
Today AXDX ranks # as BUY CANDIDATE.

AXDX stock Accelerate Diagnostics

AXDX stock
Accelerate Diagnostics

Accelerate Diagnostics Inc (NASDAQ:AXDX) – Equities research analysts at Piper Jaffray Companies issued their FY2021 earnings per share (EPS) estimates for shares of Accelerate Diagnostics in a rese... Read more
Accelerate Diagnostics (NASDAQ:AXDX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday. Accord... Read more
Accelerate Diagnostics (NASDAQ:AXDX) had its price target cut by Piper Jaffray Companies to $17.00 in a research report released on Friday, The Fly reports. They currently have an overweight rating on... Read more
Accelerate Diagnosti (AXDX) shares are being monitored by traders as the TEMA is gaining upward momentum, signifying a potential uptrend for the name. The Triple Exponential Moving Average or TEMA, is... Read more
Accelerate Diagnosti (AXDX) shares under being placed under the lens today as the Twiggs Money Flow indicator, or TMF has climbed above the zero line, indicating bullish momentum. Twiggs Money Flow In... Read more
Sentiment for Accelerate Diagnostics Inc (NASDAQ:AXDX)Accelerate Diagnostics Inc (NASDAQ:AXDX) institutional sentiment increased to 1.15 in 2018 Q3. Its up... Read more
Accelerate Diagnostics (NASDAQ:AXDX) and BioNano Genomics (NASDAQ:BNGO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strengt... Read more
The Money Flow Index of Accelerate Diagnosti (AXDX) this week has placed the shares on the radar as it nears the key 70 or 80 level. At the time of writing the MFI is holding above 60 and trending hig... Read more
Equities research analysts predict that Accelerate Diagnostics Inc (NASDAQ:AXDX) will report ($0.41) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero an... Read more
Accelerate Diagnostics (NASDAQ:AXDX) had its price objective reduced by analysts at Piper Jaffray Companies to $17.00 in a research report issued on Friday, The Fly reports. The brokerage currently ha... Read more
Looking at the longer-term MACD oscillator indicator on shares of Accelerate Diagnosti (AXDX), we can see the reading is currently Sell. The MACD is generally used to gauge bullish or bearish price mo... Read more
Monitoring the indicators for Accelerate Diagnosti (AXDX), we have noticed that the Plus Directional Indicator is currently higher than the Minus Directional Indicator. With the +DI above the -DI, tra... Read more
Investors sentiment increased to 1.15 in Q3 2018. Its up 0.22, from 0.93 in 2018Q2. It is positive, as 11 investors sold Accelerate Diagnostics, Inc. shares... Read more
Zacks Investment Research lowered shares of Accelerate Diagnostics (NASDAQ:AXDX) from a buy rating to a hold rating in a research report released on Tuesday morning. According to Zacks, “Accelerate ... Read more
Accelerate Diagnostics (NASDAQ:AXDX) had its target price cut by equities researchers at Piper Jaffray Companies to $17.00 in a research report issued to clients and investors on Friday, The Fly repor... Read more

News Feed powered by

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank